A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Inclusion Criteria:

- Men ≥ 30 years of age with non-metastatic prostate cancer, having undergone bilateral
orchiectomy or initiated ADT with GnRH agonists and is expected to continue on ADT
for at least 12 months

- Adequate visual accuracy allowing eye testing

- Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age;
Osteopenia or normal BMD if over 70 years of age

- Signed informed consent

Exclusion Criteria:

- Previous surgery for cataracts in both eyes, current diagnosis of cataracts,
cataracts surgery foreseen in the near future, or ocular disease leading to visual
loss

- Diagnosis of osteoporosis